Oxford, 19 May 2022: – Oxford Drug Design Limited (ODD), a biotechnology company with its own computing platform and machine learning platform, has raised $ 2.7 million (£ 2.2 million) in funding from existing investors ACF investors, o2h Ventures, J.Onatan Milner, a number of returning angels, and new investors as well from the United States Group R42. This leads to the fact that the total amount of grants and equity funding of the firm exceeds $ 12 million (10 million pounds).
A branch of Oxford University, ODD has been at the forefront of computer-aided drug design with its innovative dual-channel AI drug detection platform. The company has recently entered the oncology expansion phase, accelerated by its two core competencies: the world’s leading expertise in universal aminoacyl-tRNA synthetase enzymes and its computational capabilities in AI / machine learning. They capture molecular and biological features that allow the use of machine learning models with increased predictive power and accuracy of molecule selection. The company is currently focusing on unmet therapeutic needs in oncology, initially against lung cancer and colorectal cancer.
This capital growth will enable ODD to continue its research and discovery of medicines, starting with research validation concepts to validate its innovative, innovative approach against cancer. It will also create a new commercial offering of its patented AI platform for pharmaceutical and biotechnology companies. The proven OOD platform is increasingly in demand by third parties in the pharmaceutical space and is already generating revenue apart from the company’s direct work to identify oncology drugs. The investment will also go towards operational goals and further expansion ahead of this year’s Series A investment round.
Alan D. Roth, CEO of Oxford Drug Design said: “This latest funding will allow us to deploy and accelerate our successful focus on discovery led by computing design. We are excited to play a key role in innovating cancer treatments that lead to better outcomes for cancer patients worldwide. Our groundbreaking new approach must be initially validated by research-proof concepts. We are making rapid progress not only through our industry-leading drug detection program, but also through our own AI platform. This has led to a growing interest of third parties in our machine learning capabilities, so we are committed to exploiting this demand and establishing commercial efforts in the field. ”
Tim Mills, managing partner of ACF Investors said: “The Oxford Drug Design team has created an innovative platform that allows you to discover truly innovative drugs. It’s great to see them start researching to test the concept. It is also not surprising that companies operating in space have identified the possibility of using their own machine learning technology. We are excited to continue to support ODD – a testament to the strength of the company’s technology and team, that all existing investors and angels have participated in this next round, which will help expand them globally and hire key strategic personnel. “
Notes for editors
About Oxford Drug Design
Oxford Drug Design is located in Oxford, United Kingdom. Originally a dedicated company from Oxford University’s Faculty of Chemistry Professor Graham Richards OBE FRS, the company develops and develops highly innovative drugs with small molecules against cancer based on differentiated dual-core competencies. Its validated platform clearly combines innovative AI and machine learning techniques with in-depth experience in aminoacyl-tRNA syntheses, accelerating progress in the discovery and development of cancer therapies with new mechanisms of action. To learn more, visit www.oxforddrugdesign.com.